T 2232/17 (Natalizumab for diseases treatable with steroids/BIOGEN) of 24.02.2021

European Case Law Identifier: ECLI:EP:BA:2021:T223217.20210224
Date of decision: 24 February 2021
Case number: T 2232/17
Petition for review of: -
Application number: 05768245.2
IPC class: A61P 37/00 A61P 11/06 A61P 1/00 A61K 39/395
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: Natalizumab for use in treating diseases needing steroid treatment
Applicant name: Biogen MA Inc.
Opponent name: Pharmaceutical Works Polpharma SA
Board: 3.3.04
Headnote: -
Relevant legal provisions: European Patent Convention Art 100(a)European Patent Convention Art 54 European Patent Convention R 103(1)(a)European Patent Convention R 111(1)Rules of procedure of the Boards of Appeal Art 11Rules of procedure of the Boards of Appeal Art 12(4)
Keywords: -
Catchword: -
Cited cases: G 0002/88 G 0007/93 J 0009/10 T 0231/85 T 0019/86 T 0893/90 T 1101/92 T 1198/97 T 0836/01 T 1127/02 T 1399/04 T 1642/06 T 0388/09 T 2373/11 T 0734/12 T 2251/14
Citing cases: -

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division for further prosecution.